Health policy model: Long-term Predictive results associated with the management of hepatitis C virus-induced diseases in Italy

ClinicoEconomics and Outcomes Research

Volumn 6, Issue 1, 2014, Pages 303-310

  Mennini, Francesco Saverio ^a,b   Marcellusi, Andrea ^a,c   Andreoni, Massimo ^d   Gasbarrini, Antonio ^e   Salomone, Salvatore ^f   Craxì, Antonio ^g  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic hepatitis; Cost of illness; Forecast; New HCV treatment

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR;

ARTICLE; CLINICAL EVALUATION; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH ECONOMICS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; ITALY; NATIONAL HEALTH SERVICE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; VIRUS LOAD;

EID: 84902986308     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S62092     Document Type: Article

References (37)

1. World Health Organization. Sixty-third World Health Assembly. Viral hepatitis: WHA 63.18. Geneva, Switzerland; May 21, 2010.
2. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
3. European Centre for Disease Prevention and Control. Technical Report Hepatitis B and C in the EU neighborhood: prevalence, burden of disease and screening policies. September 2010. Available at: http://www.ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf. Accessed April 14, 2014.
4. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362(9401):2095-2100.
5. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334(13):815-820.
6. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75(4):522-527.
7. Fagiuali S, Mirante VG, Pompili M, et al; Monotematica AISF 2000-OLT Study Group. Liver transplantation: the Italian experience. Dig Liver Dis. 2002;34(9):640-648.
8. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9(11):S28-S34.
9. Mariano A, Scalia Tomba G, Tosti ME, Spada E, Mele A. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scand J Infect Dis. 2009;41(9):689-699.
10. White Book of AISF. Proposal of a National Plan for the Monitoring of Hepatic Diseases: Definition of Environments and Possible Interventions; 2011. Available from: http://www.webaisf.org/media/13891/libro-bianco-aisf-2011.pdf. Accessed May 13, 2014. Italian.
11. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76(3):327-332.
12. Mele A, Tosti ME, Spada E, Mariano A, Bianco E, SEIEVA Collaborative Group. Epidemiology of acute viral hepatitis: twenty years of surveillance through SEIEVA in Italy and a review of the literature. Rome: ISTISAN; 2006. Available from: http://www.iss.it/binary/publ/cont/06-12.1149070762.pdf. Accessed May 19, 2014.
13. Carosi G, Caporaso N, Gardini I, et al. Epatiti Summit 2010 - A Hidden Emergency: A Comparison of Opinions and Strategies. Available from: http://www.sosfegato.it/camo/onlus/es/Executive_Summary.pdf. Accessed May 13, 2014. 2010. Italian.
14. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology. 2013;57(6):2164-2170.
15. United Nations [webpage on the Internet]. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat, World Population Prospects: The 2010 Revision and World Urbanization Prospects: The 2010 Revision. New York, NY: United Nations; 2010. Available from: http://esa.un.org/unpd/wpp/unpp/panel_indicators.htm. Accessed November 1, 2013.
16. UC Berkeley, Max Planck Institute for Demographic Research [webpage on the Internet]. The Human Mortality Database. Rostock, Germany: Max Planck Institute for Demographic Research. Available from: http://www.mortality.org. Accessed November 1, 2013.
17. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol. 2005;76(3):327-332.
18. Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: a survey in a southern Italian town. Am J Gastroenterol. 2009;104(11):2740-2746.
19. Colombo M. How to measure the efficacy of antiviral treatments. The evaluation through "substitute" healing. Second national workshop on economics and drugs in hepatology. WEF-E 2012. Rome, Italy; February 2, 2012. I quaderni di medicina Il 24 ore Sanità Aprile 2012:12-13. Italian.
20. Mariano A, Caserta C, Pendino GM, et al. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area. Dig Liver Dis. 2009;41(7):509-515.
21. Matera G, Lamberti A, Quirino A, et al. Changes in the prevalence of hepatitis C virus (HCV) genotype 4 in Calabria, Southern Italy. Diagn Microbiol Infect Dis. 2002;42(3):169-173.
22. Marascio N, Matera G, Quirino A, et al. Eleven-year distribution pattern of hepatitis C virus in southern Italy. J Pathog. 2012; 2012:631095.
23. Kwo PY, Lawitz EJ, McCone J, et al; SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742): 705-716.
24. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
25. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
26. Zeuzem S, Andreone P, Pol S, et al; REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25): 2417-2428.
27. Jacobson IM, Brown RS Jr, Freilich B, et al; WIN-R Study Group. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007;46(4):971-981.
28. Poynard T, Colombo M, Bruix J, et al; Epic Study Group. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009;136(5): 1618-1628
29. ISTAT. (Italian National Institute of Statistics). Consumer Price Index for Currency Revaluation. Available at: http://rivaluta.istat.it/. Accessed October 1, 2013. Italian.
30. DRG 480. Liver transplantation and/or intestinal transplantation - Reimbursement rate - Lazio Region. Italian.
31. Cammà C, Petta S, Enea M, et al; WEF Study Group. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850-860.
32. Ravasio R. Cost efficacy of peginterferon α-2a+ ribavirin versus peginterferon α-2b+ ribavirin in chronic C hepatitis treatment of HIV co-infected patients. PharmacoEconomics - Italian Research Articles. 2008;10(1):37-47. Italian.
33. Ex-factory Cost AIFA - G.U. n. 287 del 10.12.2012. Available from: http://www.farmacovigilanza.asl3.liguria.it/pdf/determinazione_1_incivo.pdf. Accessed November 1, 2013.
34. European Medicines Agency. EMA/431387/2011. London, UK: European Medicines Agency; 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002332/WC500109790.pdf. Accessed November 1, 2013.
35. European Medicines Agency. EMA/644234/2011. London, UK: European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002313/WC500115507.pdf. Accessed November 1, 2013.
36. Briggs A. Economics notes: handling uncertainty in economic evaluation. BMJ. 1999;319(7202):120.
37. Taylor M. What is sensitivity analysis? Newmarket, UK: Hayward Medical Communications; 2009. Available from: http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/What_is_sens_analy.pdf. Accessed April 14, 2014.